Transforming Management Strategies by Integrating Biosimilars into the Treatment Landscape

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2023 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2023 to August 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Boehringer Ingelheim

Description:
Biosimilar products are biologic products that are highly similar to already approved biologic drugs developed for various indications. While biosimilars have some differences compared with their reference products, they are mandated to produce identical similarity from their reference biologics in terms of clinical safety and efficacy. As such, these biosimilar products promise to foster unprecedented access to a wide range of life-saving biologics while ensuring a rise in healthcare access and market sustainability. Biosimilars are expected to have a significant impact on healthcare as they revolutionize the treatments of many disease states. Biosimilars have the potential to reduce healthcare costs and expand patient access to biologic therapies. The high cost of biologic drugs in immunology imposes a substantial burden on the US healthcare system and has created numerous patient access challenges. In recent years, there has been a shift in FDA approvals for biosimilars, with multiple biosimilars for oncology-related supportive care and disease-specific therapeutic indications available on the US market. Healthcare professionals should be appropriately educated about the cost-saving benefits associated with biosimilars. These cost-savings may be significant for patient populations affected by socioeconomic challenges or other healthcare disparities that may limit access to treatment.

Upon completion of this activity, participants will be able to:

• Analyze clinical and nonclinical barriers that affect the implementation of biosimilars in clinical practice

• Discuss the available and emerging biosimilars for immunology, their indications, and their originator biologics

• Assess the efficacy, safety and immunogenicity of biosimilars via clinical trial data and real-world evidence in regard to treatment selection for patients

• Identify strategies to discuss biosimilar risks and benefits with patients who are currently treated or considering treatment with a biologic

• Examine the managed care considerations for incorporating biosimilars into an effective treatment plan and value-based care system to improve patient outcomes
  
   

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)^TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Boehringer Ingelheim

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue